Please ensure Javascript is enabled for purposes of website accessibility

Drilling Into Dentsply

By Stephen D. Simpson, Simpson, – Updated Nov 15, 2016 at 6:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clean off the plaque, and you'll find healthy results underneath.

Sometimes, you can get a fair sense of a company in just a few minutes of perusing press releases and casually reading SEC filings. Other times, you've got to dig a little deeper to see the real value of a company. That may be the case with leading dental company DentsplyInternational (NASDAQ:XRAY), since its positive aspects aren't immediately evident.

Take this quarter's revenue, for example. OK, 5.9% growth seems all right, but what about that 3.9% growth when you exclude precious metals? Likewise, 6.4% internal growth seems OK, until you see 1.2% growth in the U.S. -- which has more to do with difficult prior-year comparisons (because of some stocking/launch orders) than any fundamental weakness in the market.

It doesn't get easier as you go along, either. Gross margin looks so-so (flat, more or less) until you strip out the precious metals and see nearly a full point of improvement. And don't even get me started on the operating margin line -- it's down 1% from last year as reported, but if you adjust for precious metals and stock option expense, you see a result of 19.5%, versus 17.9% a year ago.

None of this is really high-level stuff. You can get it all from reading the 10-Q and/or listening to the call. The same documents will easily explain the seemingly low return on invested capital last year. But it's still the kind of thing that might slip through a screen or fail an initial "sniff" test. Most investors might not even realize that Dentsply is No. 1 or No. 2 in most of the markets in which it competes.

It's apparently the destiny of the dental industry to get subsumed into larger companies. After all, 3M (NYSE:MMM) is a major player, though people still think of them for Post-it Notes instead of fillings. Likewise with Sybron (NYSE:SYD), which is about to be amalgamated into Danaher (NYSE:DHR). That leaves Dentsply and tiny rivals like Schick Technologies (NASDAQ:SCHK) and National Dentex (NASDAQ:NADX).

Running the numbers through my Value-Matic 5000, I come away thinking that Dentsply is undervalued. Not by much, unfortunately, but still undervalued. While I'm a fan of bigger discounts to fair value that what I see here, I can't quibble with folks who'd think that any discount is good enough for a leading company like Dentsply, especially in such a generally stable and recurrent business.

Brush, floss, rinse, then click:

3M is a Motley Fool Inside Value recommendation. To find more great stocks trading below fair value, and swap bargain-hunting tips with hundreds of fellow Wall Street value hounds, sign up for a free 30-day guest pass.

Fool contributor Stephen Simpson owns shares of 3M, but has no financial interest in any other stocks mentioned (that means he's neither long nor short the shares). The Fool has a disclosure policy.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

3M Company Stock Quote
3M Company
MMM
$112.99 (-1.01%) $-1.15
Danaher Corporation Stock Quote
Danaher Corporation
DHR
$265.27 (-0.43%) $-1.16
DENTSPLY SIRONA Inc. Stock Quote
DENTSPLY SIRONA Inc.
XRAY
$29.98 (1.46%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.